A dual-team clinical analysis has revealed that women are more likely than men to achieve early blood pressure control after initiating antihypertensive treatment, with significant differences in stroke and ASCVD risk within three years.
Published on June 4, 2025, this observational outcome study compared sex-based treatment response among newly diagnosed hypertensive patients, confirming that women responded more quickly and with more favorable cardiovascular outcomes over time.
The findings provide new insight for clinicians looking to optimize early-stage hypertension therapy by accounting for sex differences in blood pressure regulation and event risk reduction.
Key Study Highlights
- Women were 10.7% more likely than men to reach a systolic blood pressure (SBP) under 130 mmHg within the first month of treatment.
- After three months, this advantage persisted, with women 9.5% more likely to achieve BP control compared to men.
- Over three years, women were 4.3% less likely to experience stroke and 23.8% less likely to suffer an ASCVD event.
- Results held true after adjusting for baseline blood pressure levels, suggesting inherent differences in treatment responsiveness.
Contents
Background: Why Sex Differences Matter in Hypertension Treatment
Hypertension remains a primary modifiable risk factor for stroke and cardiovascular disease across global populations.
Prior research has demonstrated physiological and risk profile differences between men and women at baseline, especially in terms of vascular function and hormone modulation.
This dual-team study (Team A: Bartelt, Deckert; Team B: Gracianette, Edwards) set out to determine whether sex impacts treatment outcomes in the first three months and long-term cardiovascular events within three years.
Study Cohort and Methodology
Researchers analyzed data from non-pregnant adults with an initial SBP >130 mmHg, confirming hypertensive status per current clinical thresholds.
Demographic variables, comorbidities, medication history, and smoking status were integrated into the statistical model to ensure comparability between sexes.
The cohort’s antihypertensive response was evaluated at one and three months, focusing on the proportion of patients achieving an SBP below 130 mmHg.
Early Results: Faster Blood Pressure Control in Women
At one month, women were 10.7% more likely than men to bring their systolic pressure below the 130 mmHg target.
By three months, the advantage was only slightly reduced, with women maintaining a 9.5% higher likelihood of achieving blood pressure control.
This trend was visualized in Figure 1, which tracked SBP normalization by sex over time.
These findings align with previous clinical observations suggesting greater antihypertensive sensitivity in women, potentially due to vascular responsiveness and hormone-mediated regulation.
Long-Term Risk Reduction: Fewer Cardiovascular Events in Women
The research team followed all participants for three years to assess incidence of stroke and ASCVD-related events.
Women were 4.3% less likely to experience a stroke and 23.8% less likely to have a major ASCVD event such as myocardial infarction or acute coronary syndrome.
These findings are illustrated in Figure 2 and were found to be independent of baseline systolic blood pressure, strengthening the study’s conclusions.
While the study did not analyze individual medication types, dosages, or adherence, the data suggests a robust sex-based difference in cardiovascular trajectory post-treatment initiation.
Clinical Implications: Personalized Hypertension Management by Sex
These findings may support more individualized hypertension strategies, particularly in newly diagnosed patients.
Women may benefit from closer monitoring early in treatment to confirm rapid BP reduction, while men may require more aggressive therapy or lifestyle optimization to achieve comparable outcomes.
Clinicians should also consider this sex-based divergence when evaluating stroke and ASCVD prevention targets, especially during the critical first year of antihypertensive therapy.
